Vytorin sees growth without nibbling on Zetia

Share this article:

Since launching last year, Schering-Plough's dual-action cholesterol-lowering product Vytorin has risen to sixth among the top nine lipid-lowering drugs, without cannibalizing sales of the firm's blockbuster cholesterol pill, Zetia.
Vytorin's 5 million prescriptions had rung up $496 million in sales as of July, according to IMS Health. And Vytorin has hardly caused a Zetia collapse. As of August, Vytorin had nabbed 7.7 percent of new prescriptions, outpacing Pravachol (pravastatin) at 6.7 percent and Crestor (rosuvastatin) at 5.8 percent.
Zetia holds 7.5 percent of new scripts and, over the same period, has reaped $1.1 billion in sales, IMS Health data show.
Vytorin is a combination of Zetia (ezetimibe) and Merck's Zocor (simvastatin). Simvastatin reduces production of LDL, or "bad cholesterol," in the liver, while Zetia reduces absorption of it in the intestine. Schering-Plough sells Vytorin and Zetia through a partnership with Merck.

 

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.